Mammogen
PrivateLast Round
Series A
Jun 3, 2026
Total Funding Raised
$33M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Mammogen operates in Healthcare & Life Sciences and is based in Newport Beach, California. Its latest recorded funding round was a Series A round in June 2026.
Mammogen is a biotechnology company that develops RNA-powered molecular diagnostic devices designed to improve the detection, diagnosis, and treatment of women's health-related diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Mammogen Comparables
Compare Mammogen with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Astrin Biosciences | 90% | |
| Syantra Inc. | 85% | |
| OncoTAb | 81% |
For institutional investors. Book with your work email.
Mammogen Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jun 3, 2026 | ||||
| Seed | Jun 30, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors grew 6247% MoM, from 15 to 952.
- Jun 3, 2026
$30M round completed.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- partners_withOct 27, 2026
Mammogen and Mammolink LLC. partner on a clinical research study that evaluates a blood-based RNA assay alongside traditional breast imaging through Mammolink LLC.'s mobile 3D mammography network across Florida on Oct 27th '26.
- is_developingOct 23, 2026
Mammogen is developing the genTRU-breast(TM) blood-based assay to provide additional information that supports earlier detection for women with dense breast tissue, as discussed on Oct 23rd '26.
- is_developingOct 23, 2026
Mammogen is developing a blood test designed to give women with dense breasts a second source of information in breast cancer screening.
- is_developingOct 20, 2026
Mammogen develops blood-based tools for earlier cancer detection, with the KATELYN-ERIN trial evaluating whether blood-based RNA signals complement imaging; Inova Schar Cancer serves as a participating site, and enrollment is expected to open later in 2026.
- hiresOct 13, 2026
Mammogen appoints Robert S. Epstein, M.D., M.S., to its Board of Directors as an Independent Director in California on Oct 13th '26.
For institutional investors. Book with your work email.
Mammogen Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Mammogen's valuation, stock price, and market status.
Is Mammogen a public or private company?
Mammogen is a private company.
What is the current stock price of Mammogen?
Mammogen is a private company, so its shares have no public market price. Caplight tracks Mammogen's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Mammogen worth (valuation)?
Valuation information for Mammogen is not publicly available.
Can I buy Mammogen stock?
Mammogen shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Mammogen's last funding round?
Mammogen's most recent funding round was Series A on June 3, 2026.
Who are the main investors in Mammogen?
Investor information for Mammogen is not publicly disclosed.
Will Mammogen IPO soon?
No public IPO plans have been announced for Mammogen.
How can I track Mammogen secondary market activity?
Caplight tracks bids, offers, and trades in Mammogen's shares on secondary markets.